Jardiance

Empagliflozin, the active ingredient in Jardiance, is a sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor presented as an oral tablet for oral administration. It is indicated for the management of type 2 diabetes mellitus, heart failure, and chronic kidney disease in adult patients.

GNH USA supplies Jardiance as a licensed, Good Distribution Practice‑compliant pharmaceutical product, sourced from the European Union market, to hospitals, pharmacies and clinics worldwide, providing reliable global procurement for qualified healthcare institutions. The company ensures quality and regulatory compliance through rigorous testing and documentation.

Jardiance (empagliflozin) is used in the management of metabolic and cardiovascular conditions related to glucose handling. - Type 2 diabetes mellitus: improves glycemic control by lowering blood glucose levels. - Heart failure: reduces risk of cardiovascular death and hospitalization for heart failure. - Chronic kidney disease: slows progression of renal function decline in adults with diabetic kidney disease.

Empagliflozin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Genital mycotic infections: increased incidence of yeast infections in the genital area. - Urinary tract infections: symptoms such as dysuria, frequency, and urgency. - Increased urination: polyuria due to osmotic diuresis. - Volume depletion: dizziness or light‑headedness from fluid loss.

Serious or Rare Side Effects: - Ketoacidosis: euglycemic diabetic ketoacidosis, a rare but serious metabolic complication. - Acute kidney injury: sudden decline in renal function, especially in patients with pre‑existing kidney disease. - Severe hypersensitivity: rash, angioedema, or anaphylactic reactions. - Fournier’s gangrene: necrotizing fasciitis of the perineum, a rare life‑threatening infection.

Before initiating empagliflozin therapy, clinicians should consider several precautionary measures to ensure safe use. - Renal function: assess eGFR and avoid use in patients with severe renal impairment. - Volume status: monitor for dehydration and advise adequate fluid intake. - Cardiovascular status: use cautiously in patients with unstable heart failure. - Ketoacidosis risk: educate patients about signs of ketoacidosis despite normal glucose levels. - Concomitant diuretics: adjust dosage to prevent excessive volume loss. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Empagliflozin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Insulin or insulin secretagogues: increased risk of hypoglycemia; dose adjustment may be required. - Loop diuretics: additive effect on volume depletion and hypotension.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce empagliflozin plasma concentrations, lowering effectiveness. - Thiazide diuretics: may enhance diuretic effect and electrolyte disturbances. - NSAIDs: can impair renal function, increasing risk of acute kidney injury.